肝胆相照论坛
标题: 病毒和宿主反应后停止长期核苷(t)ide类似物治疗在HBeAg阴 [打印本页]
作者: StephenW 时间: 2016-10-29 17:10 标题: 病毒和宿主反应后停止长期核苷(t)ide类似物治疗在HBeAg阴
Viral and Host Responses After Stopping Long-term Nucleos(t)ide Analogue Therapy in HBeAg-Negative Chronic Hepatitis B - Christoph Höner zu Siederdissen1,a,
- Franziska Rinker1,3,a,
- Benjamin Maasoumy1,
- Steffen B. Wiegand1,
- Natalie Filmann4,
- Christine S. Falk2,
- Katja Deterding1,
- Kerstin Port1,
- Carola Mix1,
- Michael P. Manns1,2,3,
- Eva Herrmann4,
- Heiner Wedemeyer1,2,3,
- Anke R. M. Kraft1,3 and
- Markus Cornberg1,3
- 1Department of Gastroenterology, Hepatology and Endocrinology
- 2Institute of Transplant Immunology, IFB-Tx, Hannover Medical School
- 3German Center for Infection Research, partner site Hannover-Braunschweig
- 4Institute of Biostatistics and Mathematical Modeling, Faculty of Medicine, Goethe-University, Frankfurt am Main, Germany
- Correspondence: M. Cornberg, Hannover Medical School, Carl-Neuberg Strasse 1, 30625 Hannover, Germany (cornberg.markus{at}mh-hannover.de).
-
Presented in part: European Association for the study of the liver, Vienna, 22-26 April 2015; International Viral Hepatitis Congress, Berlin, 26–28 June 2015.
-
↵a C. H. z. S. and F. R. contributed equally to this work.
Abstract This prospective study investigated viral and host markers after stopping long-term therapy with nucleos(t)ide analogues in noncirrhotic patients with hepatitis B e antigen–negative chronic hepatitis B. After stopping therapy, 13 of 15 patients experienced a virological relapse. Rebound of hepatitis B virus DNA and hepatitis B core-related antigen was associated with induction of plasma tumor necrosis factor, interleukin (IL) 10 , IL-12p70, CXCL10 and subsequent decline in hepatitis B surface antigen (HBsAg), with 20% HBsAg loss after long-term follow-up. The peak levels of hepatitis B virus DNA and hepatitis B core-related antigen after cessation of therapy were positively correlated with the level of HBsAg decline at week 48. Thus, stopping or interrupting NA treatment should be further investigated as a strategy to accelerate HBsAg loss.
Key words
作者: StephenW 时间: 2016-10-29 17:10
病毒和宿主反应后停止长期核苷(t)ide类似物治疗在HBeAg阴性慢性乙型肝炎
ChristophHönerzu Siederdissen1,a,Franziska Rinker1,3,a,Benjamin Maasoumy1,Steffen B.Wiegand1,Natalie Filmann4,Christine S.Falk2,Katja Deterding1,Kerstin Port1,Carola Mix1,Michael P.Manns1,2,3,Eva Herrmann4 ,Heiner Wedemeyer1,2,3,Anke RM Kraft1,3和Markus Cornberg1,3
胃肠病学,肝脏和内分泌学
2移植免疫学研究所,IFB-Tx,汉诺威医学院
3German感染研究中心,合作网站Hannover-Braunschweig
4德国法兰克福歌德大学医学院生物统计学和数学建模研究所
通讯:M. Cornberg,Hannover Medical School,Carl-Neuberg Strasse 1,30625 Hannover,Germany(cornberg.markus {at} mh-hannover.de)。
部分呈现:2015年4月22 - 26日,欧洲肝脏研究协会,维也纳;国际病毒性肝炎大会,柏林,2015年6月26日至28日。
↵ S.和F. R.对这项工作作出了同样的贡献。
抽象
这项前瞻性研究调查病毒和宿主标志物停止长期治疗核苷(t)ide类似物在乙型肝炎e抗原阴性慢性乙型肝炎的非肝硬化患者。在停止治疗后,15例患者中有13例经历了病毒学复发。乙型肝炎病毒DNA和乙型肝炎核心相关抗原的反弹与血浆肿瘤坏死因子,白细胞介素(IL)10,IL-12p70,CXCL10的诱导与随后的乙型肝炎表面抗原(HBsAg)的下降与20%的HBsAg长期随访后的损失。在治疗停止后乙型肝炎病毒DNA和乙型肝炎核心相关抗原的峰值水平与第48周的HBsAg下降水平正相关。因此,停止或中断NA治疗应进一步调查作为加速HBsAg损失的策略。
关键词
乙型肝炎病毒感染停止治疗HBsAg CXCL10 IP-10细胞因子核苷(t)ide类似物
欢迎光临 肝胆相照论坛 (http://hbvhbv.info/forum/) |
Powered by Discuz! X1.5 |